Literature DB >> 25288118

Histone H3 variants and their chaperones during development and disease: contributing to epigenetic control.

Dan Filipescu1, Sebastian Müller, Geneviève Almouzni.   

Abstract

Within the nucleus, the interplay between lineage-specific transcription factors and chromatin dynamics defines cellular identity. Control of this interplay is necessary to properly balance stability and plasticity during the development and entire life span of multicellular organisms. Here, we present our current knowledge of the contribution of histone H3 variants to chromatin dynamics during development. We review the network of histone chaperones that governs their deposition timing and sites of incorporation and highlight how their distinct distribution impacts genome organization and function. We integrate the importance of H3 variants in the context of nuclear reprogramming and cell differentiation, and, using the centromere as a paradigm, we describe a case in which the identity of a given genomic locus is propagated across different cell types. Finally, we compare development to changes in stress and disease. Both physiological and pathological settings underline the importance of H3 dynamics for genome and chromatin integrity.

Entities:  

Keywords:  H3 variants; cancer; chaperones; chromatin; development; epigenetics; histone

Mesh:

Substances:

Year:  2014        PMID: 25288118     DOI: 10.1146/annurev-cellbio-100913-013311

Source DB:  PubMed          Journal:  Annu Rev Cell Dev Biol        ISSN: 1081-0706            Impact factor:   13.827


  44 in total

1.  Unabridged Analysis of Human Histone H3 by Differential Top-Down Mass Spectrometry Reveals Hypermethylated Proteoforms from MMSET/NSD2 Overexpression.

Authors:  Yupeng Zheng; Luca Fornelli; Philip D Compton; Seema Sharma; Jesse Canterbury; Christopher Mullen; Vlad Zabrouskov; Ryan T Fellers; Paul M Thomas; Jonathan D Licht; Michael W Senko; Neil L Kelleher
Journal:  Mol Cell Proteomics       Date:  2015-08-13       Impact factor: 5.911

Review 2.  Shaping Gene Expression by Landscaping Chromatin Architecture: Lessons from a Master.

Authors:  Vittorio Sartorelli; Pier Lorenzo Puri
Journal:  Mol Cell       Date:  2018-06-07       Impact factor: 17.970

Review 3.  Point mutations in an epigenetic factor lead to multiple types of bone tumors: role of H3.3 histone variant in bone development and disease.

Authors:  Shigeaki Kato; Takeaki Ishii; Alexander Kouzmenko
Journal:  Bonekey Rep       Date:  2015-07-01

Review 4.  Chromatin dynamics during the cell cycle at centromeres.

Authors:  Sebastian Müller; Geneviève Almouzni
Journal:  Nat Rev Genet       Date:  2017-01-31       Impact factor: 53.242

Review 5.  Variants of core histones and their roles in cell fate decisions, development and cancer.

Authors:  Marcus Buschbeck; Sandra B Hake
Journal:  Nat Rev Mol Cell Biol       Date:  2017-02-01       Impact factor: 94.444

6.  Cancer-driving H3G34V/R/D mutations block H3K36 methylation and H3K36me3-MutSα interaction.

Authors:  Jun Fang; Yaping Huang; Guogen Mao; Shuang Yang; Gadi Rennert; Liya Gu; Haitao Li; Guo-Min Li
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-04       Impact factor: 11.205

Review 7.  Solid tumours hijack the histone variant network.

Authors:  Flávia G Ghiraldini; Dan Filipescu; Emily Bernstein
Journal:  Nat Rev Cancer       Date:  2021-02-10       Impact factor: 60.716

8.  Translational Opportunities for Microfluidic Technologies to Enable Precision Epigenomics.

Authors:  Yi Xu; Steven R Doonan; Tamas Ordog; Ryan C Bailey
Journal:  Anal Chem       Date:  2020-06-04       Impact factor: 6.986

Review 9.  r

Authors:  Jacqueline S Womersley; Danyelle M Townsend; Peter W Kalivas; Joachim D Uys
Journal:  Eur J Neurosci       Date:  2018-09-24       Impact factor: 3.386

10.  Chromatin Regulators as a Guide for Cancer Treatment Choice.

Authors:  Zachary A Gurard-Levin; Laurence O W Wilson; Vera Pancaldi; Sophie Postel-Vinay; Fabricio G Sousa; Cecile Reyes; Elisabetta Marangoni; David Gentien; Alfonso Valencia; Yves Pommier; Paul Cottu; Geneviève Almouzni
Journal:  Mol Cancer Ther       Date:  2016-05-16       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.